Immuneering Corp Stock Price, News & Analysis

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology firm, has priced its underwritten offering of 2,727,273 shares of Class A common stock at $11.00 per share, aiming for gross proceeds of $30 million. The proceeds will support the preclinical and clinical development of its product candidates and general corporate purposes. The offering is facilitated through a shelf registration statement filed with the SEC. Jefferies, TD Cowen, and Guggenheim Securities are acting as joint book-running managers. The press release includes forward-looking statements, cautioning that actual results may vary due to economic factors and associated risks.

Immuneering Corporation (Nasdaq: IMRX) presented promising initial data from their Phase 1 trial of IMM-1-104 at the AACR Annual Meeting. This novel therapy targets RAS mutant tumors and demonstrated significant pharmacokinetic (PK) levels, achieving over 2,000 ng/mL with a median half-life of approximately 1.94 hours. The drug was well tolerated, having no dose limiting toxicities (DLTs) or serious adverse events (SAEs) reported. The company indicated an acceleration in the study timeline, with the recommended Phase 2 dose (RP2D) now anticipated in early 2024, earlier than originally expected. Initial pharmacodynamic (PD) results showed over 90% inhibition of pERK in patients, supporting the potential efficacy of IMM-1-104. Further updates on the trial are expected periodically.

Immuneering Corporation (Nasdaq: IMRX) recently announced its participation in the 22^nd Annual Needham Virtual Healthcare Conference on April 19, 2023, from 12:45 - 1:25 pm ET. The presentation will provide insights into the company's pipeline, platform, and business strategy.

Key management participating includes Ben Zeskind, CEO; Scott Barrett, CMO; Brett Hall, CSO; and Mallory Morales, VP of Finance. The event will feature a virtual presentation followed by 1x1 investor meetings. All presentations will be webcast live and archived for 30 days on Immuneering's website.

Immuneering is focused on developing medicines for cancer patients, particularly aiming for a universal-RAS therapy through deep cyclic inhibition of the MAPK pathway. Its lead candidate, IMM-1-104, is currently in Phase 1/2a trials for RAS mutation-related advanced solid tumors.

Immuneering Corporation (Nasdaq: IMRX) has announced a virtual Investor Event at 9:00 a.m. ET on April 18, 2023, coinciding with a data presentation on its universal-RAS program IMM-1-104 at the American Association for Cancer Research Annual Meeting 2023. The company focuses on developing innovative oncology therapies, particularly targeting RAS mutations, with its lead candidate currently in a Phase 1/2a study for advanced solid tumors. Immuneering aims to achieve universal activity in cancer treatment while minimizing harm to healthy cells.

Immuneering Corporation (Nasdaq: IMRX) has appointed Harold E. Brakewood as Chief Business Officer, bringing over 25 years of experience in biotechnology and pharmaceuticals. His mandate includes corporate development and commercialization strategies to support the company's universal-RAS therapy initiative. Brakewood's prior experience includes leadership roles at Regeneron Pharmaceuticals and Merck, where he was integral in launching several cancer treatments. His expertise will aid in advancing Immuneering's lead product, IMM-1-104, currently in clinical trials for patients with RAS-driven tumors.

Immuneering Corporation (Nasdaq: IMRX) announced the presentation of data on its lead program IMM-1-104 at the AACR annual meeting, scheduled for April 14-19, 2023, in Orlando, Florida. This research showcases a pharmacogenomics approach that identifies patient tumor profiles for clinical translation in a Phase 1/2a trial for patients with advanced solid tumors harboring RAS mutations. The presentation, titled “Humanized 3D tumor models that are mutationally aligned with AACR GENIE patients,” will highlight how advanced modeling predicts the effectiveness of IMM-1-104 against RAS-addicted tumors. The trial aims for selective cancer cell targeting while sparing healthy cells.

Immuneering Corporation (Nasdaq: IMRX) announced the first patient has been dosed in the Phase 1/2a clinical trial of IMM-1-104 targeting advanced solid tumors with RAS mutations. Initial pharmacokinetic (PK) and safety data are anticipated in mid-2023, with further updates on pharmacodynamic (PD) modeling and safety data expected in the second half of 2023. The company expects to file an IND for IMM-6-415 in Q4 2023 and has extended its cash runway into Q4 2024 by suspending its discovery-stage neuroscience programs. Full-year net loss for 2022 was $50.5 million, or $1.91 per share, reflecting increased R&D and G&A expenses.